Renaissance Technologies (RenTech)'s UPB Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC (Rentech)) currently holds 16,400 shares of Upstream Bio, Inc. (UPB) worth $445,260, representing 0.00% of the portfolio. First purchased in 2025-Q4, this recently established position has been held for 1 quarters.
Based on recent 13F filings, Renaissance Technologies (RenTech) has initiated a new position in UPB, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Upstream Bio (UPB) Holding Value Over Time
Track share changes against reported price movement
Quarterly Upstream Bio (UPB) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +16,400 | New Buy | 16,400 | $27.15 |
Renaissance Technologies (RenTech)'s Upstream Bio Investment FAQs
Renaissance Technologies (RenTech) first purchased Upstream Bio, Inc. (UPB) in Q4 2025, acquiring 16,400 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Upstream Bio, Inc. (UPB) for 1 quarters since Q4 2025.
Renaissance Technologies (RenTech)'s largest addition to Upstream Bio, Inc. (UPB) was in Q4 2025, adding 16,400 shares worth $445,260.
According to the latest 13F filing for Q4 2025, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC (Rentech), owns 16,400 shares of Upstream Bio, Inc. (UPB), valued at approximately $445,260.
As of the Q4 2025 filing, Upstream Bio, Inc. (UPB) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Upstream Bio, Inc. (UPB) was 16,400 shares, as reported at the end of Q4 2025.